Product Information

文献

Yasui K et al. (JAN 2003) Stem cells (Dayton,Ohio) 21 2 143--51

Differences between peripheral blood and cord blood in the kinetics of lineage-restricted hematopoietic cells: implications for delayed platelet recovery following cord blood transplantation.

Cord blood (CB) cells are a useful source of hematopoietic cells for transplantation. The hematopoietic activities of CB cells are different from those of bone marrow and peripheral blood (PB) cells. Platelet recovery is significantly slower after transplantation with CB cells than with cells from other sources. However,the cellular mechanisms underlying these differences have not been elucidated. We compared the surface marker expression profiles of PB and CB hematopoietic cells. We focused on two surface markers of hematopoietic cell immaturity,i.e.,CD34 and AC133. In addition to differences in surface marker expression,the PB and CB cells showed nonidentical differentiation pathways from AC133(+)CD34(+) (immature) hematopoietic cells to terminally differentiated cells. The majority of the AC133(+)CD34(+) PB cells initially lost AC133 expression and eventually became AC133(-)CD34(-) cells. In contrast,the AC133(+)CD34(+) CB cells did not go through the intermediate AC133(-)CD34(+) stage and lost both markers simultaneously. Meanwhile,the vast majority of megakaryocyte progenitors were of the AC133(-)CD34(+) phenotype. We conclude that the delayed recovery of platelets after CB transplantation is due to both subpopulation distribution and the process of differentiation from AC133(+)CD34(+) cells. View Publication

产品号#：

04064

04960

04902

04900

04961

04901

04963

04962

04970

04971

产品名：

MethoCult™ H4034 Optimum启动试剂盒套装

MegaCult™-C胶原蛋白和不含细胞因子的培养基

胶原蛋白溶液

MegaCult™-C培养基无细胞因子

MegaCult™-C胶原蛋白和细胞因子培养基

MegaCult™-C细胞因子培养基

双室载玻片试剂盒

MegaCult™-C cfu染色试剂盒

MegaCult™-C不含细胞因子完整试剂盒

MegaCult™-C细胞因子完整试剂盒

文献

Schiedlmeier B et al. (MAR 2003) Blood 101 5 1759--68

High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation.

Ectopic retroviral expression of homeobox B4 (HOXB4) causes an accelerated and enhanced regeneration of murine hematopoietic stem cells (HSCs) and is not known to compromise any program of lineage differentiation. However,HOXB4 expression levels for expansion of human stem cells have still to be established. To test the proposed hypothesis that HOXB4 could become a prime tool for in vivo expansion of genetically modified human HSCs,we retrovirally overexpressed HOXB4 in purified cord blood (CB) CD34+ cells together with green fluorescent protein (GFP) as a reporter protein,and evaluated the impact of ectopic HOXB4 expression on proliferation and differentiation in vitro and in vivo. When injected separately into nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice or in competition with control vector-transduced cells,HOXB4-overexpressing cord blood CD34+ cells had a selective growth advantage in vivo,which resulted in a marked enhancement of the primitive CD34+ subpopulation (P =.01). However,high HOXB4 expression substantially impaired the myeloerythroid differentiation program,and this was reflected in a severe reduction of erythroid and myeloid progenitors in vitro (P textless.03) and in vivo (P =.01). Furthermore,HOXB4 overexpression also significantly reduced B-cell output (P textless.01). These results show for the first time unwanted side effects of ectopic HOXB4 expression and therefore underscore the need to carefully determine the therapeutic window of HOXB4 expression levels before initializing clinical trials. View Publication

产品号#：

04434

04444

09600

09650

产品名：

MethoCult™H4434经典

StemSpan™ SFEM

文献

Lam AC et al. (DEC 2001) Transfusion 41 12 1567--76

Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice.

BACKGROUND: Ex vivo expansion of cord blood (CB) hematopoietic stem and progenitor cells increases cell dose and may reduce the severity and duration of neutropenia and thrombocytopenia after transplantation. This study's purpose was to establish a clinically applicable culture system by investigating the use of cytokines,serum-free media,and autologous plasma for the expansion of CB cells and the engraftment of expanded product in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. STUDY DESIGN AND METHODS: Enriched CB CD34+ cells were cultured in four media (Iscove's modified Dulbecco's medium with FCS,Gibco; X-Vivo-10,BioWhittaker; QBSF-60,Quality Biological; and StemSpan SFEM,Stem Cell Technologies) with four cytokine combinations (thrombopoietin [TPO],SCF,Flt-3 ligand [FL] with and without G-CSF,and/or IL-6). The effect of autologous CB plasma was also investigated. The read-out measures were evaluated on Days 8 and 12. After expansion at the optimized condition,cultured cells were transplanted into sublethally irradiated NOD/SCID mice. The engraftment of human CD45+ cells and subsets in the bone marrow,spleen,and peripheral blood was determined. RESULTS: QBSF-60 or StemSpan SFEM supported high yields of early progenitors (CD34+ cells,textlessor= 64.8-fold; CD34+CD38- cells,330-fold; CFU-granulocyte erythroid macrophage megakaryocyte [GEMM],248-fold) and CFUs of the myeloid (CFU-GM,407-fold) and erythroid (BFU/CFU-E,144-fold) lineages. The expansion of the megakaryocytic lineage was consistently higher in X-Vivo-10 (CFU-megakaryocyte,684-fold). Autologous plasma promoted colony formation but reduced CD34+ cells and CFU-GEMM. The addition of G-CSF or IL-6 improved cell yields; G-CSF was more effective for committed progenitors. Expansion products from cultures in QBSF-60 with the cytokines engrafted and differentiated into the myeloid and lymphoid lineages in NOD/SCID mice. CONCLUSION: The data supported the strategy of expansion. The optimized condition may be applicable to clinical expansion for the abrogation or reduction of posttransplant cytopenia. View Publication

产品号#：

09600

09650

产品名：

StemSpan™ SFEM

技术手册

Human Colony-Forming Unit (CFU) Assays Using MethoCult™

产品号#：

00217

00217UK

00215

00215GER

00215UK

00602

00603

00606

00607

00608

00609

04436

04064

04100

04230

04236

04431

04434

04444

04464

04531

04535

04545

04536

04564

09300

04035

04330

04034

04044

04435

04445

04534

04544

04437

04447

00215US.4

00215CA.3

00215GER.3

0

产品名：

MethoCult™ SF H4436

MethoCult™ H4034 Optimum启动试剂盒套装

MethoCult™ H4100

MethoCult™H4230

MethoCult™SF H4236

MethoCult™H4431

MethoCult™H4434经典

MethoCult™ H4434 Classic启动试剂盒套装

MethoCult™H4531

MethoCult™H4535富集无EPO

MethoCult™ H4535 Enriched，不含EPO

MethoCult™ SF H4536

入门套件MethoCult™H4534经典无EPO

含有10% 牛血清白蛋白（BSA）的 Iscove's MDM

MethoCult™H4035 Optimum无EPO

MethoCult™H4330

MethoCult™H4034 Optimum

MethoCult™H4435富集

MethoCult™H4534经典无EPO

MethoCult™表达

造血祖细胞检测标准化培训课程

技术手册

STEMCELL Quality Control Kits

产品号#：

00650

00651

产品名：

人骨髓质量控制试剂盒

人脐带血质量控制试剂盒

Differences between peripheral blood and cord blood in the kinetics of lineage-restricted hematopoietic cells: implications for delayed platelet recovery following cord blood transplantation.

High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation.

Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice.

欢迎您关注STEMCELL Technologies的微信公众平台